Loading
Revelation Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by TIDMARSH GEORGE F, was filed 19 Apr 2023.
Revelation Biosciences, Inc.: what insiders have been doing
Revelation Biosciences, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). From 22 October 2025 to 22 October 2026, the disclosure feed for Revelation Biosciences, Inc. logged 24 filings by 5 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 24 filings here. Over the whole record (from 2020), the tally stands at 8 purchases and 13 sales. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -8.9 m USD.
Insider buying of Revelation Biosciences, Inc. has been absent for the past year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
Elsewhere in the same sector, our signals recently picked up insider purchases at UCB. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
54
Thresholds
n/a
Buy Volume
€268,526
8 ops. · all time
Sell Volume
€6M
13 ops. · all time
Since the insiders bought
- -93.1%Entry US$6,278.40 · Close at T+365 US$430.08
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.75
Analyst consensus
2 analysts1.00/5
US$112.00Target US$124.25(+3213%)US$136.50
Income statement
EBITDA-US$9M
Net income-US$14.9M0.0% margin
Valuation
PER (trailing)0.8x
PER (forward)-0.2x
P/Book1.5x
Beta-0.06
Balance sheet & cash
Market capUS$2.1M
Total debtUS$746.8k
Free Cash Flow-US$8.3M
Debt / Equity7%
Profitability & ownership
ROE-154.8%
ROA-78.7%
% insiders12.3%
% institutions12.9%
Last declaration on 18 August 2026
Declarations54 total
32,011 shares0Common StockSEC:0001193125-26-355659:0
208,073 shares0Common StockSEC:0001193125-26-355661:0
208,073 shares0Common StockSEC:0001193125-26-355661:1
208,073 shares0Common StockSEC:0001193125-26-355661:2
208,076 shares0Common StockSEC:0001193125-26-355663:0
32,011 shares0Common StockSEC:0001193125-26-355658:0
32,011 shares0Common StockSEC:0001193125-26-355662:0
13,285 shares@ US$1.100.36% mcap2.2% of flowCommon StockSEC:0001193125-26-201764:0
10,115 shares@ US$1.130.28% mcap1.0% of flowCommon StockSEC:0001193125-26-201769:0
1,591 shares@ US$1.854.7% of flowCommon StockSEC:0001193125-26-039700:0
2,261 shares@ US$1.856.6% of flowCommon StockSEC:0001193125-26-039695:0
1,661 shares@ US$1.875.0% of flowCommon StockSEC:0001193125-26-039693:0
13,100 shares@ US$1.653.2% of flowCommon StockSEC:0001193125-26-039686:0
8,521 shares@ US$1.861.4% of flowCommon StockSEC:0001193125-26-039690:0
78,145 shares@ US$0.9010.4% of flowCommon StockSEC:0001193125-26-010642:0
41,981 shares@ US$0.9061.3% of flowCommon StockSEC:0001193125-26-010625:0
41,981 shares@ US$0.9061.4% of flowCommon StockSEC:0001193125-26-010613:0
41,981 shares@ US$0.9060.2% of flowCommon StockSEC:0001193125-26-010586:0
532,829 shares@ US$0.9042.1% of flowCommon StockSEC:0001193125-26-010648:0
15,625 shares@ US$1.2832.5% of flowCommon StockSEC:0001193125-25-260419:0
15,625 shares@ US$1.2831.9% of flowCommon StockSEC:0001193125-25-260426:0
390,614 shares@ US$1.2844.0% of flowCommon StockSEC:0001193125-25-260423:0
390,614 shares@ US$1.2874.4% of flowCommon StockSEC:0001193125-25-260417:0
15,625 shares@ US$1.2832.6% of flowCommon StockSEC:0001193125-25-260415:0
30,095 shares@ US$3.8711.6% of flowCommon StockSEC:0000950170-25-020109:0
25 of 54 declarations
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a United States-based clinical-stage biotechnology company listed on the NASDAQ Capital Market in the United States. Founded in May 2020, the company has built its strategy around a scientific thesis focused on rebalancing inflammation to optimize health and potentially address both acute and chronic disease. Its operational base is in San Diego, California, a major U.S. life sciences hub that provides access to clinical development talent, scientific infrastructure, and specialist capital markets.
From a business perspective, Revelation is not yet a commercial-stage pharmaceutical company. It is primarily a research-and-development organization whose value is driven by its pipeline rather than by product sales. Public filings indicate that the company has devoted most of its resources since inception to corporate setup, financing, research, and the advancement of its product candidates. Its development efforts have centered on clinical programs in renal and inflammatory disease areas, including assets referenced in SEC filings as product candidates for acute kidney injury and chronic kidney disease. For investors, this makes Revelation a classic pipeline-dependent biotech rather than a revenue-generating healthcare platform.
Read moreShow less
In competitive terms, Revelation operates as a small-cap clinical-stage biotech in a highly crowded and capital-intensive market. Its competitive position depends less on scale and more on scientific differentiation, clinical execution, and the ability to generate data that can support future development and, eventually, regulatory pathways. The company competes indirectly with larger pharmaceutical groups, better-capitalized biotechnology peers, and academic translational programs pursuing similar therapeutic themes. As with many early-stage biotechs, valuation is highly sensitive to trial outcomes, financing availability, and dilution risk.
Recent company developments highlight that Revelation has continued to rely on capital markets to fund operations. SEC filings from 2025 and 2026 show a continued financing focus, including a public offering announced in May 2025 that generated approximately $4 million in gross proceeds to support clinical and operating needs. Recent quarterly disclosures also emphasize limited cash resources and the ongoing need to raise additional capital, which is a central issue for micro-cap biotech investors. In addition, Form 4 insider transaction filings underscore active monitoring of executive and director share activity, a relevant signal for governance-focused investors.
Overall, Revelation Biosciences is a high-risk, high-optionalities health and pharma story on NASDAQ in the United States. Its investment case will likely hinge on clinical progress, data quality, and financing execution rather than on current operating scale or commercial diversification.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
